Treatment complexities and the cytotoxicity of anticancer drugs to normal cells often results in therapeutic failure. Biodegradable nanoparticles have gained attention as drug carriers due to their physicochemical characteristics. Nanoparticles are able to encapsulate anticancer drugs and deliver them to target malignant cells while sparing normal cells. Since lung cancer usually arises in lung epithelium, localized drug delivery could be an alternative strategy to effectively treat this disease. Encapsulation of lung cancer drugs in nanoparticles may facilitate intact drug delivery, avoid first-pass metabolism, and reduce cytotoxicity to normal cells, as well as being attractive to patients. However, nanoparticles should be formulated in such a way as to facilitate entrance, deposition, retention, and permeability on targeted lung tissues and escape mucociliary clearance and phagocytosis. Additionally, the patient's diversity related to lung cancer type, stage of disease, and physical fitness should be considered when formulating a nanocarrier and a delivery device. The potential of localized drug delivery for lung cancer using nanoparticles is reviewed here.
Introduction
Lung cancer is the most commonly diagnosed cancer (11.6% of all the cases), and the leading cause for cancer deaths (18.4% of all cancer deaths) among both men and women worldwide 1 . Lung cancer is a heterogeneous disease that arises when genetic and epigenetic alterations happen in lung epithelium 2 . Most lung tumors are the result of frequent exposure to tobacco smoke. However, exposure to exogenous carcinogens, such as diesel exhaust, radon, household fumes and radiation in domestic and occupational environments, has been estimated to cause 10 -25% of lung cancers in non-smokers 3, 4 . Based on clinical and therapeutic characteristics, lung cancer is broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into squamous cell carcinoma (SCC), adenocarcinoma (ADC), and large cell carcinoma (LCC). SCLC usually found perihilar on the main bronchus while SCC initiated on main stem lobar or segmental bronchi. ADC and LCC emerge on peripheral lung tissues [5] [6] [7] .
The selection of the treatment regimen for lung cancer depends on the stage of cancer and the patient's physical condition. Generally, all the stages of SCLC are treated with chemotherapy or chemoradiotherapy since surgery is inadequate to control the disease due to the rapid doubling and metastatic characteristics of the malignant cells 8 . Surgical resection is the frequent treatment of choice for stage 1 NSCLC as the tumor is often localized to one area of the lung and has not spread to draining lymph nodes. However, for stage 2 and 3 NSCLC, chemotherapy or chemoradiotherapy, post surgery or neoadjuvant chemotherapy followed by surgery is given, depending on the extent of tumor invasion into the chest cavity. Neoadjuvant chemotherapy shrinks the tumors and controls distal occurrence to nearby tissues. Chemoradiotherapy is the only treatment option available for stage 4 lung cancer patients as this ensures systemic drug delivery to metastatic lesions [9] [10] [11] . Current lung cancer treatments often cause adverse short-term and long-term side effects, including nausea, ulcers, cardiotoxicity, increased risk of developing other cancers, cytotoxicity to healthy cells, and induction of a broad spectrum of degenerative diseases 12 . For example, cisplatin, a drug commonly given to lung, breast and ovarian cancer patients, and doxorubicin, used to treat breast cancer, show nephrotoxicity (20 -30%) and cardiotoxicity (3-20%), respectively 13, 14 . Even if lung cancer is properly treated, recurrence of the disease is common due to the presence of occult micro-metastatic cancer cells, development of drug resistance and enrichment of cancer stem cells; this results in a poor survival rate among lung cancer patients 15, 16 . . Most lung cancer therapeutics are administered via intravenous injections. Switching to the non-invasive oral delivery of chemotherapeutics is desirable but challenging due to the potential for poor drug solubility, low chemical stability and permeability, irritation of the gastrointestinal (GI) tract, and phase I and phase II metabolism in the GI tract and hepatic tissues. For instance, oral administration reduces the therapeutic efficacy of the taxanes, paclitaxel, and docetaxel, due to their higher affinity for drug transporters (P-glycoprotein), low drug solubility and metabolism by cytochrome P450 (CYP3A) enzymes 19 . As previously reviewed, inhalation facilitates non-invasive local and systemic drug delivery for treating many respiratory diseases, including cancer 20, 21 . Direct delivery of chemotherapeutics to lung tissues may cause toxicities, poor delivery efficiency, multidrug resistance, and severe side effects as it does not permit selective delivery on cancer cells. The encapsulation of chemotherapeutics in nanocarriers, such as liposomes, dendrimers, micelles, minimizes cytotoxicity, enables targeted drug delivery, sustained drug release and avoids drug resistance. Codelivery of gefitinib and vorinostat in hyaluronan-based copolymer nanoparticles minimizes the hepatic toxicity, enhances persistent drug release and inhibits orthotopic lung tumors in mice compared to the free drugs 22 . Conjugating the growth factor, folic acid, on dendrimers improves targeted co-delivery of siRNA and cisplatin resulting in apoptosis of the folate receptor overexpressing H1299 lung cancer cells with negligible toxicity towards MRC9 lung fibroblasts 23 . Liu and colleagues have demonstrated the potential of using liposomal nanoparticles in effectively delivering 1,25-dihydroxy vitamin D3, which promotes epithelial differentiation and inhibits NSCLC, into erlotinib resistant HCC827 lung cancer cells 24 .
It is, therefore, necessary to understand the benefits of using nanocarriers in effectively delivering chemotherapeutics with minimum systemic cytotoxicity to normal cells. This review discusses nanotechnology-based drug carriers and their potential for delivering localized cancer treatments to target lung cancer with minimal adverse side effects.
Pulmonary drug delivery, absorption, metabolism, and clearance

Drug delivery and distribution
The respiratory system coordinates with the circulatory system to supply oxygen from the outside environment to cells of the body and remove carbon dioxide from the body. The respiratory system is broadly divided into two sections; the upper respiratory tract consisting of the nose, nasal cavity and pharynx; and the lower respiratory tract consisting of the larynx, trachea, bronchi (airway region), and the alveoli absorption region. Inhaled drugs can deposit via impaction, sedimentation, interception or diffusion, depending on the particle size, airflow rate and location in the respiratory system. Table 2 and Figure  1 present the effects of particle size on site of deposition within the respiratory tract. Most particles greater than 10 µm are deposited by impaction the oropharyngeal region and are subsequently swallowed, resulting in poor bioavailability 25 . Micromolecules, <5 µm size, can reach the deep peripheral lung alveoli, and hence may be a very good candidate for systemic drug delivery via the respiratory route. Most particles between 0.1 -1 µm in size are exhaled from the lung tissues 26, 27 . However, small particles (<0.1 µM, <100 nm) are quickly deposited on lung surface by Brownian motion, 28 and could, therefore, be effective as drug carriers. For example, 20 nm size silver nanoparticles are evenly distributed and deposited by diffusion among all five lobes of rat lungs after one day or five days nose only exposure 29 . In contrast, intratracheal inhalation of 20 nm gold nanoparticles results, for the most part, in deposition in the caudal lungs of Wistar rats. Some of them are deposited on the airway epithelium and alveoli as well 30 . As Yang et al suggested, lung biodistribution of nanoparticles (18 -480 nm) is determined by means of the delivery method. Intratracheal instillation encourages more central deposition whereas more homogenous central to peripheral deposition is found in ventilator-assisted aerosol inhalation in preclinical experimental models 31 . In humans, 50 -100 nm particles are deposited mostly in peripheral airways, and the deposition rate is affected by lung capacity, lung health and breathing depth 32 .
Pulmonary drug absorption
The large alveolar surface relative to the small airway and alveolar volume provides a good superficial layer for pulmonary drug delivery and absorption 33 . Drug transfer across the lung epithelium occurs by passive diffusion, facilitative and active transport via solute transport carriers that reside on the apical and basolateral surface of the plasma membrane, and vesicle-mediated transport ( Figure 2 ). The pseudostratified columnar airway epithelium (approximately 60 µm thickness) and thin alveolar epithelium (0.2 µm thickness) enhance the absorption of both hydrophilic and lipophilic drug molecules 27 . Once the drug molecules attach to the surfactant layer, some of them will traverse through and reach the lining fluid and epithelium cells. Hydrophilic drugs absorb through paracellular diffusion (prolongs absorption), while most lipophilic drugs are absorbed via transcellular diffusion. In addition, macromolecules (MW is > 40 kDa) remain on the surface of the lung epithelium for a long time and absorb slowly; in contrast, small molecules (MW < 40 kDa) can reach blood circulation within a few minutes of inhalation 26, 34 . Drug transport proteins reside on the cytoplasmic membrane of the lung epithelium and are highly localized in bronchial and alveolar regions 35 . The organic cation/ carnitine transporter 1 is located on the luminal side of the airway epithelium and facilitates drug influx into the lung epithelial cells. Multidrug resistance-associated protein 1 (MRP1) is located on the basolateral side of the human bronchial epithelial cells and facilitates drug efflux from the lung epithelial cells 35 . A higher expression level of MRP1 has been found in NSCLC, which mediates resistance to carboplatin and paclitaxel co-treatment, resulting in poor therapeutic effect 36 . Macromolecules, larger than 50 kDa (e.g., albumins), absorb via receptor-mediated A) The inhaled aerosol drugs deposit in the airway and alveolar tissues, depending on their particle size, by impaction (larger molecules at oropharyngeal and tracheal region), sedimentation (at the central and peripheral lung tissues) and both diffusion and sedimentation (nanoparticles at bronchioles and alveoli). B) Large, poorly soluble, drugs deposited at trachea and bronchus are moved upward by mucociliary beat and end up in the GI tract. However, microparticles can penetrate mucus that lies above the ciliary surface and either reside in it or pass through the airway epithelium. C) in the alveolus, alveolar macrophages clear the microparticles through phagocytosis. However, most nano molecules rapidly reach the respiratory vasculature through the thin alveolar and endothelial walls at lung periphery. D) The most common mechanisms of pulmonary drug absorption; 1. Paracellular absorption of most hydrophilic molecules through tight intercellular junctions, 2. Endocytosis of large molecules through membrane-bound receptors, and 3. Transcellular absorption of lipophilic drug molecules through the plasma membrane. Note that illustrations are not drawn according to scale. transcytosis 37 . For instance, biotinylated epidermal growth factor on gelatine nanoparticles (200 nm) shows enhanced cellular uptake compared to non-biotinylated gelatine nanoparticles in A549 adenocarcinoma cells 38 . Similarly, transferrin receptor-mediated DNA uptake via endocytosis was observed by Melguizo et al. in HeLa cells in vitro 36 ( Figure 2 ). The surface charge is a key determinant of bioavailability and cellular uptake of nanoparticles. Li and colleagues have demonstrated that surface functionality plays a major role in bioavailability, cellular internalization, and pulmonary toxicity of carbon nanotubes. Anionic nanoparticles (polyetherimide (PEI) surface functionality) have higher cell internalization capability compared to that of the cationic particles (COOH and PEG functionality groups). However, PEInanotubes induce chronic inflammation and fibrosis in murine lungs compared to anionic nanoparticles 39 . Many investigators have reported pulmonary inflammation and induced immune responses after installation of cationic nanoparticles in mouse experimental models and suggested their use as immune vaccines [40] [41] [42] . In contrast, installation of negatively charged silver nanoparticles have induces chronic lung inflammation and the infiltration of macrophages, lymphocytes and neutrophils and cardiac toxicity 43 . Cationic nanoparticles are easily internalized into macrophages and dendritic cells 42, 44 . Additionally, surface charge density, either negative or positive, is positively correlated with the adsorption and translocation of particles over the respiratory surfactant layer 45 .
Pulmonary drug excretion or clearance
Once inhaled and deposited, particles and/or drugs are eliminated from the respiratory system via mucociliary clearance, coughing, phagocytosis, systemic absorption or by metabolism in the mucus lining or by lung epithelial cells. Physical and chemical properties of drugs have a major impact on the efficiency of drug clearance. For example, nanoparticles are more rapidly absorbed into the circulatory system compared to macromolecules. Some nanoparticles are cleared by alveolar macrophages (phagocytosis) or slowly move back towards the airway epithelium 46 . Binding of surfactant proteins and lipids to nanoparticles triggers the interaction of macrophages with nanoparticles 47 . In contrast, most of the proteinbased small molecular drugs are rapidly absorbed into the pulmonary circulation intact due to avoidance of macrophage clearance 26, 48 . Molecules that are trapped in the thick mucus gel layer move upward towards the pharynx by the metachronous beat of airway cilia that extend from the trachea to the terminal bronchioles, after which they are usually routed to the GI tract ( Figure 1 [B]).
Pulmonary drug metabolism
Metabolism in lung tissue differs substantially from metabolism in hepatic and GI tissues. The primary detoxification phase I enzymes, cytochrome P450s, have the highest level of expression in hepatocytes and enterocytes but are also expressed in the lungs where they protect against inhaled or ingested xenobiotics, such as cigarette smoke, toxic gas, and air-borne drugs 27 . For example, CYP1B1, CYP2B6, CYP2B7, CYP2E1 CYP2J2, CYP3A5, and CYP1A1 are expressed in human lung tissues and alveolar macrophages 27, 49 . These enzymes catalyze the hydroxylation of molecules and enhance their hydrophilicity, thereby facilitating the excretion process. The resulting phase I metabolites gain further hydrophilicity through conjugation to glucuronic acid, glutathione, acetate, and sulfate via the phase II enzymes, UDP glucuronosyl transferase, glutathione-s-transferase (GST), N-acetyltransferase (NAT) and sulfotransferases (SULT), further facilitating their elimination from lung tissues 50, 51 . The expression level and pattern of phase I and phase II metabolizing enzymes are low in respiratory epithelium compared to hepatic and GI tissues. Thus, local metabolic deactivation is less of a barrier to systemic drug absorption for inhaled versus orally administered drugs. In contrast, nanoparticles show rapid absorption, less metabolism, and nearly 100% bioavailability when administered via the respiratory tract. For instance, Chono and colleagues reported an enhanced uptake of insulin-encapsulated dipalmitoyl phosphatidylcholine liposomes (100 nm) in mouse lungs compared to the administration of free insulin (5 kDa) 52 .
Emerging pharmaceutical technologies: nanoparticles for pulmonary drug delivery
The pulmonary route of systemic drug delivery has gained recent attention for the treatment of respiratory and non-respiratory diseases. The possibility of direct delivery of smaller doses of the drug to target lung tissues, needleless delivery, and self-operative capability is an attractive option for chemotherapy of lung cancer.
Nanoparticles are submicron sized (<1 µm) colloidal particles developed from organic or inorganic materials, including lipids, proteins, natural or artificial polymers, and metals. Drugs can be entrapped in a polymer-based cavity or adsorbed to the surface of the nanoparticle, which can easily extravasate from blood vessels to the target tissue due to the nanoparticle's small size. Based on their structural dimension and chemical nature, nanoparticles are classified as liposomes, micelles, polymer-based nanoparticles, peptide-based nanoparticles, and dendrimers 53 (Fig. 3) . Scientists have also investigated the potential of creating a hybrid of different types of nanoparticles that together will enhance treatment efficiency by delivering dual drugs. For example, Wu and colleagues have prepared hybrid nanoparticles containing cisplatin and paclitaxel, which are first-line drugs used in the treatment of advanced lung cancer, that consist of a thermosensitive dual drug hydrogel comprised of a cisplatin-containing copolymer, poly(ethylene glycol)-poly(ε-caprolactone)-poly(ethylene glycol), and a paclitaxel-loaded polymeric micelle, monomethoxy poly(ethylene glycol)-poly(ε-caprolactine). Interestingly, intratumoral injection of the dual drug hydrogel effectively reduces tumor volume, tumor cell proliferation, and microvesicle formation, as well as prolonging the survival of mice xenografted with A549 lung cancer cells 54 . Some researchers have tested alternative approaches to enhancing the penetration of solid lung tumors by nanoparticles. Inhalation of losartan and telmisartan aerosols, prior to intravenous injection of fluorescent polystyrene nanoparticles (200 nm), significantly enhanced the penetration and intratumoral distribution of the nanoparticles by inhibiting transforming growth factor-β1 and collagen-I expression 55 . An in vitro study of short-interfering RNA loaded chitosan nanoparticle and co-encapsulation with doxorubicin in poly-L-lactide showed effective silencing of the multidrug resistance gene in H69AR lung cancer, compared to results obtained with non-encapsulated forms 56 .
Liposomes
Liposomes are typically composed of phospholipids arranged as bilayer vesicles. Depending on their physical structure and size, liposomes are classified as multilamellar vesicles that consist of several concentric bilayers of phospholipid (1.0 -5.0 µm), and large (50 -100 nm) and small (30 -50 nm) unilamellar vesicles composed of a single bilayer 57 . The phospholipid bilayer enables liposomes to carry both hydrophilic and hydrophobic drugs (Fig. 3) and allows co-delivery of drugs to enhance the therapeutic efficacy of chemotherapeutics 58 . The amount of drug that is encapsulated is determined by both the size and number of concentric bilayers 59 . The circulation life of a liposome depends on its size and surface functionalization. Liposome formulations composed of phospholipids and cholesterol are effective and biocompatible for pulmonary drug delivery as both constituents are inherently present in lung surfactants and plasma membranes 20 . A dual functional liposome, which is decorated with a modified peptide by incorporating 2, 3-dimethyl maleic anhydride and 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine, overcomes the multidrug resistance in lung cancer 60 . The flexibility of modifying liposome surface properties opens novel avenues to develop them as effective drug carriers to directly target cancer.
Because of sustained release properties over a prolonged period, the possibility of localized drug administration, and biodegradable properties, liposomes have gained traction as an effective and less invasive pulmonary drug delivery system. For instance, Liu and colleagues found that liposome-encapsulated ciprofloxacin, an antibiotic used to treat respiratory infections, exhibits increased bioavailability, enhanced localized drug delivery, inhibits bacterial growth and reduces lung tissue irritation and systemic drug concentration 61 . The evidence in favor of using liposomes as a pulmonary anticancer drug delivery vehicle is presented in Table 3 . Table 3 . Evidence supporting the use of nano-encapsulated chemotherapeutics for lung cancer treatment compared to the free drugs.
Amararathna 
Micelles
Micelles are nano-size structures with a self-assembled amphiphilic core-shell, that spontaneously form in aqueous environments by hydrophobic interactions. They are prepared by dissolving individual polymeric chains in aqueous solution above a threshold concentration (critical micelle concentration; the concentration of surfactant in water which initiates the formation of micelles) and solution temperature (critical micelle temperature; the lowest temperature, at which surfactants form micelles in water) 62, 63 . Most micelles are made up of amphiphilic polymers such as polyethylene glycol (PEG) and polyethylene oxide (PEO), which are FDA-approved excipients 64 . The selection of polymeric materials in the manufacturing of micelles is important, as the polymers determine micelle size and shape, stability and drug retention. Incorporation of hydrogenated soy phosphatidylcholine changes the shape of PEG-PE micelles and reduces drug retention within the nanoparticle by decreasing electrostatic interactions between the cargo (doxorubicin) and PEG-phosphatidylethanolamine (PE) 65 . Because of lower molecular mass and easy renal clearance of polymeric residuals after micelle degradation, unimeric micelles are more suitable for drug delivery than di-block (hydrophilic-hydrophobic) or triblock (hydrophilichydrophobic-hydrophilic) particles (Fig 4) . Micelles composed of a hydrophobic core that facilitates the loading of hydrophobic drugs, such as paclitaxel and tamoxifen, and a hydrophilic shell, which acts as a barrier for particle aggregation protein binding and opsonization, degrade in the systemic circulation prior to reaching the target tissue 62 . Two different anticancer drugs can co-encapsulate together in micelles to enhance the drug loading efficiency and synergize the anticancer effect 66 . For example, coencapsulation of paclitaxel with β-lapachone (LPC), a novel cytotoxic drug activated by quinone oxidoreductase 1 (NQO1), in poly(ethylene glycol)-b-poly(D, L-lactic acid) inhibits the crystallization of LPC, enhances LPC drug loading efficiency and shows synergistic cytotoxicity against A549 non-small cell lung cancer cells 67 .
Dendrimers
Dendrimers (also known as dendritic polymers) are nanoparticles that resemble a series of tree-like branches surrounding a central core. Figure 5 illustrates the basic structure of a dendrimer. The multi-factional surface shell and hyper-branching tree-like interior with cavities facilitates conjugation or encapsulation of drug molecules. In addition, the ability to modify the active terminal surface by acylation or PEGylation improves dendrimer bioavailability, while conjugating target peptides or receptor proteins with dendrimers enhances targeted drug delivery 68 . Molecular weight and composition determine the absorption efficiency and retention of dendrimers in the lungs. For example, the inhalation of higher molecular weight (78 kDa) dendrimers results in reduced absorption rate and enhanced drug retention in the lung tissues compared to small molecular weight (<22 kDa) dendrimers 69 . In addition, respiratory delivery of doxorubicin-conjugated PEGylated dendrimers leads to prolonged drug residence in lung tissues and effective lung tumor burden reduction in rats 70 . Drug delivery can be enhanced by decorating dendrimers with targeting peptides, as is the case with generation 4 (G4) dendrimers coupled to non-small cell lung cancer targeting peptides (sequence RCPLSHSLICY) 71 . Anti-epidermal growth factor receptor antibody-conjugated poly(amidoamine) dendrimers have a stable and higher binding affinity in vitro and in vivo, in cyclin E-overexpressing transgenic mice 68 .
Polymer-based nanoparticles
Polymeric nanoparticles are colloidal systems, in which the therapeutic agents are either embedded within the polymeric matrix or adsorbed to the surface of the nanoparticles ( Figure 6 ). There are two types of polymerbased nanoparticles; nanospheres, in which the drug is uniformly distributed, and nanocapsules, in which the drug is entrapped into a cavity surrounded by a polymer layer 57, 72 . However, to be an effective drug delivery system, the selected polymer should be 1) biocompatible, 2) nonimmunogenic, 3) easy to synthesize and inexpensive, 4) water-soluble, and 5) biodegradable in vivo to minimize possible toxicity resulting from accumulated nonmetabolized polymeric particles 72 . In some cases, a linker is inserted between the polymer and the therapeutic agent to facilitate stability and prevent liberation into the circulation after cellular delivery. For example, 90% of lactoferrin-chondroitin sulfate nanoparticles (192 nm) containing doxorubicin and ellagic acid deposit in deep lung tissues, thereby increasing the therapeutic index of the drug 73 . Polymers used in drug delivery systems can be either natural or synthetic. Chitosan, gelatin, cellulose, and alginate are natural, biodegradable polymers. Polylactic acid, poly(alkyl cyanoacrylates), polyanhydrides and poly(lactide-co-glycolide) (PLGA) are examples of synthetic biodegradable polymers used in nanoparticle preparation 57 .
Peptide-based nanoparticles
Small peptides such as growth factors and neurotransmitters are involved in many physiological functions in the human body. These naturally occurring peptide molecules comprising <30 amino acids are not often used clinically owing to their poor chemical and physical stability and short half-life in systemic circulation due to glomerular filtration and serum protein degradation 74, 75 . However, small peptides have many advantageous properties as therapeutic agents since they can easily penetrate cells and release drugs in response to tissue pH. For example, peptide conjugated liposomes have effectively internalized into mitochondria by reversing its surface charge (negative to positive) in the tumor extracellular environment (pH ~6.8) 60 . Hence, peptidebased nanoparticles have gained attention as gene and drug transporters to the targeted tissues 74 . For instance, intravenous administration of cisplatin and methotrexate, separately mixed with K16ApoE (Mayo Proteomic Core Facility) transporter peptide, increased the drug penetration and brain-uptake of both drugs compared to free drug injections 76 . Similarly, peptide, RLWMRWYSPRTRAYGC has selective cell-penetrating ability and targets drug delivery in A549 xenografted lung cancer cells 77 . Enzymatic degradation can be minimized and the half-life of peptides in blood circulation improved by modifying the physical and chemical structure of peptide molecules. Previously used strategies include structural modification of peptides by conjugating with d albumin, albumin-binding antibody or cell-penetrating peptides, PEGylation to enhance circulation half-life, and binding with nuclear localizing sequences to enhance the targeted drug delivery 75, 78 . Since the pulmonary mucosal surface is rich in anti-protease enzymes, it is naturally permeable to small molecule peptides and proteins after their inhalation. Therefore, pulmonary delivery of peptide-based nanoparticles may result in faster absorption and increased local, as well as systemic, bioavailability in comparison to subcutaneous or intravenous injections. Popular materials used in peptidebased nanoparticle preparation are listed in Table 4 .
Aerosolized anticancer treatments for lung cancer
Even though systemic drug delivery via nanocarriers is more efficient than conventional intravenous drug administration for lung cancer, direct anticancer drug delivery by inhalation (see Table 5 ) has several additional advantages. Aerosols provide direct delivery of anticancer drugs to the target cancer cells and thus increased therapeutic efficacy at lower drug concentrations. In this regard, direct topical application of paclitaxel nanoparticles enhances treatment efficacy at a significantly lower drug concentration (1 mg/kg) compared to intravenous administration of paclitaxel nanoparticles (2 mg/kg) 79 . Moreover, direct delivery avoids adverse side effects common in systemic anticancer treatments. For example, the administration of aerosolized doxorubicinnanoparticles through dry powder aerosolizers has reduced cardiotoxicity, prolonged survival (up to 140 days vs. <50 days), and suppressed the lung metastasis in mice compared to the intravenous delivery of the free drug as well as doxorubicin nanoparticles 80 . The use of ligands for specific receptors expressed by tumor cells enhances targeted drug delivery and results in minimal side effects. For instance, inhalation of doxorubicincontaining nanoparticles decorated with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) results in a synergistic inhibition of tumor metastasis in mice when compared to naked doxorubicin-containing nanoparticles. TRAIL specifically binds to death receptors 4 and 5 expressed on metastatic lung cancer cells in mice, thereby enhancing targeted drug delivery and cancer cell apoptosis 81, 82 . Additionally, incorporation of the common lung chemotherapeutics, doxorubicin, and cisplatin, into a gelatin nano aerosol complexed with epidermal growth Amararathna M, Goralski K, Hoskin DW, Rupasinghe HPV. Pulmonary Nano-Drug Delivery Systems for Lung Cancer: Current Knowledge and Prospects. J Lung Health Dis (2019) 3(2): [24] [25] [26] [27] [28] factor ligand demonstrates increased localized drug concentration (4 µg/g lung tissue 24 h post administration), lower systemic concentrations and enhanced therapeutic effect in a mouse model of metastatic lung cancer 83, 84 . In contrast, inhalation of an anticancer drug, gemcitabine, results in pulmonary toxicities such as bronchospasm in lung cancer patients, but no systemic toxicity, such as neurotoxicity, nephrotoxicity, and hematologic toxicity 85 . In addition, aerosolized nanoparticles containing doxorubicin and ellagic acid show promising antitumor efficacy in BALB/c mice compared to inhalation of the combined free drugs and intravenous injection of the drug-nano complex 73 . Importantly, aerosol generators do not need invasive needle-based delivery and the patients can selfadminister the anticancer drug. However, while respiratory anticancer drug delivery shows great potential, drug toxicities are still possible. Therefore, further research and optimization of nanoparticle delivery of anticancer drugs via the respiratory route are required.
Conclusions and future directions
Inhalation of chemotherapeutic nanoparticles assures a more effective method of intact drug delivery to the lung in comparison to conventional intravenous drug delivery, as well as eliminating or minimizing any drug-related toxicity to normal tissues ( Table 5 ). The opportunity for drug delivery only to targeted tissues by nanoparticles through PEGylation, peptide, or receptor ligand conjugation provides a mechanism to produce an effective concentration of drug locally with reduced doses having less cytotoxicity compared to topical application of the free drug. Many studies have confirmed that cytotoxicity is lower when chemotherapeutics are encapsulated in nanocarriers versus delivering them as free drug solutions. Further, needleless drug administration would enhance the patient's psychological status and willingness to attend a regular treatment program, especially in relation to painful administration of chemotherapeutics. Nanoparticle size, mass median aerodynamic diameter, chemical structure, drug encapsulation efficiency, bioavailability, and biodegradability, as well as the type of delivery device, should be taken into consideration when designing an inhalable anticancer drug carrier for lung cancer. For example, the mass median aerodynamic diameter of nanoparticles affects the nanoparticle distribution, deposition, and mucociliary and/or phagocytotic clearance of drugs in the alveolar epithelium. Furthermore, PEGylation enhances the retention and bioavailability of drug carriers on lung epithelium for prolonged localized drug delivery.
Even though lung cancer arises on lung epithelium that is accessible to inhalable aerosol drugs, the center of origin can be anywhere in the lung. Usually, small cell lung cancer arises centrally on bronchus epithelium, while non-small cell lung cancer, such as adenocarcinoma and large cell carcinoma, arises on peripheral bronchioles and alveolar epithelium. Therefore, the drug carriers should localize to central airways for treating small cell lung cancer, while for adenocarcinoma carrier localization should be peripheral. Aerosol nanoparticles at 5 -10 µm geometric range could be effective for treating small cell lung cancer as they deposit by impaction on central airway epithelium. However, anticancer drugs need to reach deep into lung tissues to treat adenocarcinoma. Gravitational sedimentation and diffusion of small particles (0.1 -3 µm size) can effectively deposit these nanoparticles in peripheral lung tissues and could be effective in treating adenocarcinoma.
The stage of lung cancer (localized or metastasis) varies from individual to individual, and hence the drugcontaining nanocarrier should be designed to address both localized and systemic drug delivery. Drugs need to reside within lung tissues for sustained drug release to treat localized lung cancer, while systemic absorption of the drug is necessary for treating stage IV lung tumors, which have already spread to the distal lymph nodes or other organs, such as liver, bones and brain. Localized and systemic drug delivery via the pulmonary route at the same time is challenging because of the aerodynamic nature of the nanoparticles. The use of multilamellar liposomes is a good approach for localized anticancer drug delivery, whereas the use of dendrimers is a better option for systemic anticancer drug delivery owing to their diversity in particle size.
Generally, lung cancer is diagnosed at a later stage of the disease. Trouble with breathing and taking short, frequent breaths are common among advanced stage lung cancer patients. Even for the early stage lung cancer patients, difficulty in breathing can be common after a lobectomy. The delivery of an effective drug dose, especially to peripheral lung tissues, can be quite challenging as the total lung capacity and tidal volume is low in such patients. This may directly affect the efficacy of inhalers as the breathing velocity affects pulmonary distribution and deposition of aerosolized drug particles or nanocarriers. The introduction of a spacer and a power source to generate and deliver nano size molecules could help patients to effectively inhale drugs deep into lung tissues.
The topical application of chemotherapeutic agents incorporated into nanoparticles is promising compared to topical application of free drugs or intravenous injection of drug-containing nanocarriers; however, there are limitations that need to be addressed by additional research. Liposomes and lipid-based nanoparticles are less stable, easily undergo oxidative degradation, and agglomerate, resulting in poor drug effectiveness. Since most lung cancers are diagnosed at an advanced stage, it is necessary to develop nanoparticles and a delivery strategy to reach both central and peripheral lung tissues, as well as systemic circulation, to facilitate drug access to local and distal metastatic tumor nodules. Most lung cancer patients have a smoking history or long-term exposure to other occupational or environmental toxicants that affect the structure of lung epithelium. These patients also have a frequent cough and difficulty in breathing due to cancer or poor physical condition, age, or asthma. These patient-related conditions directly affect the breathing rate, vital lung capacity, and inhaler efficiency, which generate irregularities in drug distribution, deposition, and absorption in lung tissues. Thus, patient conditions should be taken into consideration when developing novel aerosol delivery devices and designing treatment plans. Consequently, research should focus on the search for effective nanocarriers with higher stability and the capacity for deagglomeration, as well as enhanced penetration into solid tumors. Modification of the physical (mass median diameter and porosity) and chemical (amphiphilic particles, add target ligands, and stable polymers) properties of nanoparticles could be useful to maintain stability and prevent agglomeration during storage. It is also possible to incorporate a drug into multiple nanoparticles, such as liposomes, dendrimers, micelles to achieve a synergistic enhancing effect on local and systemic delivery. A combination of topical and systemic drug-nanoparticle delivery should be considered to deliver an effective drug dose for patients who have breathing difficulties.
In summary, inhalation of anticancer drugs is an attractive treatment strategy, owing to its noninvasive characteristics and capacity for patient-driven delivery. As the drug delivery mechanism can have a large influence on drug efficacy, 1) locality of lung cancer, 2) stage of lung cancer and 3) the respiratory rate and volume of individuals are important to consider when designing a delivery vehicle for anticancer drugs.
